Disclosed is the use of a compound of formula I wherein X is O, S, SO or SO2 R1 is halogen trihalomethyl , - OH, C1- 7 alkyl C1alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy , naphthylmethoxy, phenoxymethyl, - CH2- OH, - CH2- CH2- OH, C1alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio , acetyl , nitro or cyano, or phenyl, phenylCalkyl or phenyl Calkoxy each phenyl group thereof being optionally substituted by halogen CF Calkyl or Calkoxy R is H halogen trihalomethyl Calkoxy Calkyl phenethyl or benzyloxy R H halogen CF OH Calkyl Calkoxy benzyloxy phenyl or Calkoxymethyl each of R and R independently is H or a residue of formula (a) wherein each of R and R independently is H or Calkyl optionally substituted by halogen and n is an integer from 1 to 4 or a pharmaceutically acceptable salt hydrate solvate isomer or prodrug thereof or a compound of formula II wherein R is halogen trihalomethyl Calkyl Calkoxy Calkylthio Calkylsulifinyl Calkylsulfonyl aralkyl optionally substituted phenoxy or aralkyloxy R is H halogen trihalomethyl Chalkyl Calkoxy aralkyl or aralkyloxy R is H halogen CF Calkyl Calkoxy Calkylthio or benzyloxy R is H Calkyl phenyl optionally substituted benzyl or benzoyl or lower aliphatic Cacyl R is H monohalomethyl Calkyl Calkoxy methyl Calkyl thiomethyl hydroxyethyl hydroxypropyl phenyl aralkyl Calkenyl or alkynyl R is H or Calkyl R is H Calkyl or a residue of formula (a) as defined above X is O S SO or SO and n is an integer of 1 to 4 or a pharmaceutically acceptable salt hydrate solvate isomer or prodrug thereof in the manufacture of a medicament for the treatment or prophylaxis of scLE and related autoimmune cutaneous conditions.
